HK1209314A1 - Dosing regimen for janus kinase (jak) inhibitors - Google Patents

Dosing regimen for janus kinase (jak) inhibitors Download PDF

Info

Publication number
HK1209314A1
HK1209314A1 HK15109423.1A HK15109423A HK1209314A1 HK 1209314 A1 HK1209314 A1 HK 1209314A1 HK 15109423 A HK15109423 A HK 15109423A HK 1209314 A1 HK1209314 A1 HK 1209314A1
Authority
HK
Hong Kong
Prior art keywords
therapeutically effective
effective dose
mammal
jak
methyl
Prior art date
Application number
HK15109423.1A
Other languages
English (en)
Chinese (zh)
Inventor
．岡薩雷斯
A．J．冈萨雷斯
．科斯格羅夫
S．B．科斯格罗夫
．馬爾帕斯
P．B．马尔帕斯
．斯特格曼
M．R．斯特格曼
．科勒德
W．T．科勒德
Original Assignee
硕腾服务有限责任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1209314(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 硕腾服务有限责任公司 filed Critical 硕腾服务有限责任公司
Publication of HK1209314A1 publication Critical patent/HK1209314A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HK15109423.1A 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors HK1209314A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US61/674,289 2012-07-20
US201361815803P 2013-04-25 2013-04-25
US61/815,803 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (1)

Publication Number Publication Date
HK1209314A1 true HK1209314A1 (en) 2016-04-01

Family

ID=48901189

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15109423.1A HK1209314A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors
HK18110906.2A HK1252083A1 (zh) 2012-07-20 2018-08-23 Janus激酶(jak)抑制剂的给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18110906.2A HK1252083A1 (zh) 2012-07-20 2018-08-23 Janus激酶(jak)抑制剂的给药方案

Country Status (25)

Country Link
US (1) US9522151B2 (enExample)
EP (1) EP2874630B1 (enExample)
JP (2) JP6022063B2 (enExample)
KR (2) KR20170034949A (enExample)
CN (2) CN108354938A (enExample)
AU (1) AU2013292547B2 (enExample)
BR (1) BR112015000808A2 (enExample)
CA (1) CA2878867C (enExample)
CY (1) CY1121436T1 (enExample)
DK (1) DK2874630T3 (enExample)
ES (1) ES2707627T3 (enExample)
HK (2) HK1209314A1 (enExample)
HR (1) HRP20182088T1 (enExample)
HU (1) HUE042771T2 (enExample)
IN (1) IN2015DN00370A (enExample)
LT (1) LT2874630T (enExample)
MX (1) MX360857B (enExample)
NZ (1) NZ703152A (enExample)
PL (1) PL2874630T3 (enExample)
PT (1) PT2874630T (enExample)
RS (1) RS58242B1 (enExample)
SI (1) SI2874630T1 (enExample)
SM (1) SMT201900044T1 (enExample)
WO (1) WO2014015107A1 (enExample)
ZA (1) ZA201500134B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
CN107098908B (zh) 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
DK3915989T3 (da) * 2019-01-30 2023-09-18 Felicamed Biotechnology Co Ltd Jak inhibitor and preparation method therefor
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2022133420A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
CA3303899A1 (en) * 2021-03-16 2026-05-13 Hk Inno.N Corporation Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
AU2022263067A1 (en) * 2021-04-22 2023-11-02 Shenzhen Chipscreen Biosciences Co., Ltd. Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
RS53382B (sr) 2008-08-20 2014-10-31 Zoetis Llc Jedinjenja pirol [2,3-d]pirimidina

Also Published As

Publication number Publication date
WO2014015107A1 (en) 2014-01-23
ES2707627T3 (es) 2019-04-04
MX2015000871A (es) 2015-05-07
BR112015000808A2 (pt) 2017-06-27
CN104470525A (zh) 2015-03-25
HRP20182088T1 (hr) 2019-02-08
RS58242B1 (sr) 2019-03-29
HK1252083A1 (zh) 2019-05-17
EP2874630B1 (en) 2018-12-05
JP6022063B2 (ja) 2016-11-09
KR20170034949A (ko) 2017-03-29
IN2015DN00370A (enExample) 2015-06-12
CA2878867C (en) 2018-01-09
SMT201900044T1 (it) 2019-02-28
CY1121436T1 (el) 2020-05-29
PT2874630T (pt) 2019-01-31
LT2874630T (lt) 2019-02-11
CN108354938A (zh) 2018-08-03
US20150126535A1 (en) 2015-05-07
EP2874630A1 (en) 2015-05-27
AU2013292547A1 (en) 2015-01-22
SI2874630T1 (sl) 2019-04-30
KR20150028299A (ko) 2015-03-13
JP2017019816A (ja) 2017-01-26
NZ703152A (en) 2016-03-31
US9522151B2 (en) 2016-12-20
CA2878867A1 (en) 2014-01-23
HUE042771T2 (hu) 2019-07-29
PL2874630T3 (pl) 2019-04-30
JP2015522620A (ja) 2015-08-06
ZA201500134B (en) 2016-08-31
AU2013292547B2 (en) 2017-05-04
DK2874630T3 (en) 2019-01-28
MX360857B (es) 2018-11-20

Similar Documents

Publication Publication Date Title
HK1252083A1 (zh) Janus激酶(jak)抑制剂的给药方案
EA030003B1 (ru) Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
US20190083500A1 (en) Combination of PI3K Inhibitor and C-Met Inhibitor
US20210353627A1 (en) Novel quinazoline egfr inhibitors
US12622912B2 (en) Application of pyrido[1,2-a]pyrimidinone analog
WO2025184572A1 (en) Wee1 inhibitor combination therapy
JP2021119129A (ja) Ｐｒｍｔ５阻害剤を用いて乾癬および他の自己免疫状態を治療する方法
EP2104502B1 (en) Compositions and methods of reducing side effects and toxicity of methotrexate when given as orotate derivatives
US20230255912A1 (en) Compositions and methods for treating crp-mediated diseases
KR20240009964A (ko) 결절성 양진 치료를 위한 jak1 경로 억제제
CN118984704A (zh) 治疗卵巢癌的药物组合和方法
TWI872311B (zh) 一種吡啶并[1,2-a]嘧啶酮類似物的應用
US20230293544A1 (en) Methods, dosage regimens, and compositions for treating hidradenitis
EP0505640B2 (en) Improved therapeutic method
US20230416244A1 (en) Imidazoquinoline compound having anti-inflammatory, antifugal, antiparasitic, and anticancer activity
HK40115079A (en) Methods, dosage regimens, and compositions for treating hidradenitis
TW202302110A (zh) 包含ｊａｋ３／ｊａｋ１／ｔｂｋ１選擇性抑制劑的藥物組合物及其醫藥用途